All In Biotech

Drug Trial Radar · NCT00948766

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44

Last checked: Nov 20, 2026Latest source record: Aug 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 716 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

716

Actual

Start

Jul 2009

Primary completion

Jan 2012

Study completion Jun 2012

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Jul 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm\^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm\^2 patch) in patients with Severe Dementia of the Alzheimer's Type in a 24-week study. The extension study obtained additional safety and efficacy data, as well as provided the higher dose rivastigmine patch to all patients who completed the core study for an additional 24 weeks.

Conditions

  • Alzheimer's Disease

Interventions

  • Rivastigmine 4.6 mg/24 h (5 cm^2)Drug

    Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.

  • Rivastigmine 9.5 mg/24 h (10 cm^2)Drug

    Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.

  • Rivastigmine 13.3 mg/24 h (15 cm^2)Drug

    Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.

  • PlaceboDrug

    Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24Time frame: Baseline of the core study to Week 24 of the core study
  2. Core Study: Change From Baseline in the Severity Impairment Battery (SIB) Score at Week 24Time frame: Baseline of the core study to Week 24 of the core study

Locations

95 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Research Advantage Inc./Neurological. Physicians of Arizona, Inc

    Tempe, Arizona

  • Northwest Neuro Specialist, PLLC

    Tucson, Arizona

  • IHS Research Center Inc.

    Conway, Arkansas

  • East Bay Physicians Medical Group

    Berkeley, California

  • ATP Clinical Research, Inc.

    Costa Mesa, California

  • Neuro Pain Medical Center

    Fresno, California

  • Margolin Brain Institute

    Fresno, California

  • Collaborative Neuroscience Network Inc.

    Garden Grove, California

  • PCND Neuroscience Research Institute Inc./The Center for Memory and Aging

    Poway, California

  • Anderson Clinical Research

    Redlands, California

  • San Francisco Clinical Research Center

    San Francisco, California

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • Viking Clinical Research Center

    Temecula, California

  • Collaborative Neuroscience Network, Inc

    Torrance, California

  • Senior Care of Colorado

    Aurora, Colorado

  • Clinical Research Studies Dept. of Clinical Science and Medical Education

    Boca Raton, Florida

  • Quantum Laboratories Memory Disorder Center

    Deerfield Beach, Florida

  • Brain Matters Research, Inc.

    Delray Beach, Florida

  • Neurologic Consultants, PA

    Fort Lauderdale, Florida

  • White-Wilson Medical Center

    Fort Walton Beach, Florida

  • MD Clinical

    Hallandale, Florida

  • Sunrise Clinical Research, Inc

    Hollywood, Florida

  • Compass Research, LLC

    Orlando, Florida

  • Integrity Research, LLC

    Pensacola, Florida

  • Neurostudies, Inc.

    Port Charlotte, Florida

  • Stedman Clinical Trials, LLC

    Tampa, Florida

  • Center for Clinical Trials

    Venice, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Alexian Brothers Neuroscience Institute

    Elk Grove Village, Illinois

  • Elkhart Clinic, LLC

    Elkhart, Indiana

  • Indiana University Medical Center

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • MidAmerica Neuroscience Reseach Institute

    Lenexa, Kansas

  • Precise Clinical Research Solutions

    Manhattan, Kansas

  • LSU Health Sciences Center/Department of Psychiatry Psychopharmacology Research Clinic

    Shreveport, Louisiana

  • J. Gary Booker, MD APMC

    Shreveport, Louisiana

  • Pharmasite Research

    Baltimore, Maryland

  • The Samuel and Alexia Bratton Memory Clinic, William Hill Inc

    Easton, Maryland

  • Neuroscience Research of the Berkshires

    Pittsfield, Massachusetts

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.